Cagrilintide is an amylin analogue being developed in weight-management research. It is distinct from semaglutide. CagriSema names the investigational combination of cagrilintide and semaglutide.
How its mechanism differs from GLP-1 medicines
Cagrilintide belongs to the amylin-analogue class; semaglutide is a GLP-1 receptor agonist. Different biological targets are not a recommendation to combine substances independently.
Separate single-agent and CagriSema evidence
REDEFINE 1 studied CagriSema with single-agent comparison groups. Results must be attributed to the relevant group. The developer also describes the phase 3 RENEW programme for cagrilintide alone; these programmes do not verify a generic labelled vial.
What a product name cannot establish
Cagrilintide or CagriSema wording does not verify formulation, purity or registration. These sources do not establish outcomes from pairing the substance with tirzepatide or retatrutide.
Frequently asked questions
Is cagrilintide semaglutide?
No. They are different substances with different biological targets.
What does CagriSema mean?
It names the investigational cagrilintide–semaglutide product, not any independently prepared mixture.
Does CagriSema evidence apply to every cagrilintide brand?
No. Distinguish the trial group, formulation and the specific product’s evidence.
Read next
What is semaglutide? Wegovy, Ozempic and brand-specific evidence · What is tirzepatide? Medicine names, mechanism and listing differences · What is retatrutide? Mechanism, evidence and listing names
Sources
Information checked 10 September 2026. Research and medicine labels above are separate from evidence for this listing image.
For general name or label questions, contact LINE: @musclestationth
Revision note
Earlier outcome promises and combination advice remain withdrawn. This revision adds substance context and separates research programmes.